Seven US Democratic Senators are reportedly calling or regulators to review the proposed acquisition of Allergan, which makes Botox, by Canada’s Valeant Pharmaceuticals.

According to reports, lawmakers want the $54 billion hostile takeover offer reviewed, citing former Valeant buyouts that lead to job cuts.

The company reportedly cut hundreds of jobs in …read more

Source: Global Competition Law Blogs